History
-
2019
-
Q301 Phase 2a Results presented at 2019 American Academy of Dermatology Annual Meeting in Washington DC
03.02
-
-
2018
-
TELACEBEC(Q203) U.S. FDA Fast Track Designation
11.12
-
Capital raise of 40 billion KRW
10.19
-
Received grant from Korea Drug Development Fund for TELACEBEC(Q203) Phase 2a study
10.01
-
US FDA approval for TELACEBEC(Q203) phase 2a study
07.16
-
US FDA approval for Q301 phase 2b study
06.21
-
Completion of TB TELACEBEC(Q203) phase 1b study
05.05
-
Confirmation of “Telacebec” as a generic name for Q203 by INN & USAN
03.01
-
-
2017
-
South Africa MCC approval for Q203 phase 2a study
12.20
-
Posted 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Q701 & Q702 / Q901 )
10.26
-
Published in European Journal of Medicinal Chemistry. 136 (2017);420-427 (Title : Synthesis and structure-activity relationships of novel fused ring analogues of Q203 as antitubercular agents)
08.18
-
EDCTP(European & Developing Countries Clinical Trials Partnership) grant awarded to PanACEA consortium to run Q203 clinical studies
02.28
-
Published in European Journal of Medicinal Chemistry. 125 (2017);807-815 (Title : Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203)
01.05
-
-
2016
-
US FDA approval for Q203 Phase 1b study
08.29
-
Completion of Q301 phase 2a study
05.19
-
Initial public offering on Korea Exchange (KRX:115180)
02.29
-
-
2015
-
Q203 U.S. FDA Orphan Drug Designation
12.28
-
Received grant from Korea Drug Development Fund for Q203 phase 1 study
12.16
-
US FDA IND approval for Q203 phase 1 study
07.23
-
US FDA approval for Q301 phase 2a study
03.12
-
In-licensed CDK7 inhibitor program from Max Planck Innovation / Lead Discovery Center
02.27
-
Umbrella partnership agreement signed with Max Planck Innovation / Lead Discovery Center
02.06
-
-
2014
-
Capital raise of 15.5 billion KRW
06.09
-
Published in Journal of Medicinal Chemistry. 57(12);5293–5305 (Title : Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent)
05.28
-
Russia and CIS rights for Q203 licensed to Infectex (a subsidiary company of Maxwell Biotech Group, Russia)
01.21
-
-
2013
-
Published in Nature medicine. 19(9);1157-60. (Title : Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis)
08.04
-
Capital raise of 3 billion KRW
05.10
-
Received grant from Korea Drug Development Fund for Q203 preclinical IND enabling studies
04.30
-
In-licensed Axl inhibitor program from Max Planck Innovation / Lead Discovery Center
02.21
-
-
2012
-
Capital raise of 3 billion KRW
09.19
-
-
2011
-
Company name change to “Qurient Co., Ltd”
10.21
-
Capital raise of 1 million USD
02.09
-
-
2010
-
Won Gate II competition for 1M USD investment by Novartis Venture Fund
09.02
-
In-licensed anti-tuberculosis antibiotics programs from Institut Pasteur Korea
03.04
-
-
2009
-
Series A finance of 4 billion KRW
11.20
-
-
2008
-
Foundation of Qurient (formerly Quro Science Co. Ltd.)
07.02
-